Table 1.
Subject/patients demography and lung function data
| Group |
||||||
|---|---|---|---|---|---|---|
| Parameter | HC | ACO | Asthma | COPD -CS |
COPD -ES |
NLFS |
| Patients/subjects, n | 28 | 12 | 14 | 11 | 12 | 13 |
| GINA diagnosis: mild persistent/moderate/severe, n | N/A | 0/0/4 | 5/1/8 | N/A | N/A | N/A |
| ICS treatment, n | 0 | 7 | 6 | 0 | 0 | 0 |
| ICS dose, mcg/day | 0 | 800 | 750 | 0 | 0 | 0 |
| No. of OCS courses, n | 0 | 1.5 (0–10) | 2 (0–6) | 0 | 0 | 0 |
| Gold diagnosis: Stage I and II/Stage III, n | N/A | 7/1 | N/A | 11/0 | 12/0 | N/A |
| Sex (M/F), n | 9/20 | 6/6 | 6/8 | 7/4 | 6/6 | 9/4 |
| Age, yr | 61 (20–76) |
70 (52–77) |
62 (26–81) |
60 (52–69) |
62 (53–69) |
46 (30–66) |
| Smoking history, pack·years | 0 | 22.5 (15–103) |
0 | 46.3 (18–78.8) |
54.8 (18.0–150.5) |
35 (10.5–57) |
| FEV1 %predicted | 99.5 (75–129) |
58 (35–96) |
81.5 (48–108) |
82.7 (68–100) |
80.0 (54.5–104.7) |
98 (78–114) |
| FEV1/FVC% | 78.4 (67–88) |
65.5 (31–84) |
74 (52–90.2) |
63.9 (46.6–67.6) |
58.5 (38.0–68.0) |
76 (69–96) |
Values are median and range. ACO, asthma COPD overlap; COPD, chronic obstructive pulmonary disease; COPD-CS, COPD current smokers; COPD-ES, COPD exsmokers; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GINA, Global Initiative for Asthma; HC, healthy control; ICS, inhaled corticosteroids; n, no. of subjects/patients; N/A, not applicable; NLFS, normal lung function smokers; OCS, oral corticosteroids.